Our scope is protein glycosylation. Glycan structures are involved in changes in the stability and function of biopharmaceuticals and are altered along with host cell species and culture conditions. In some production conditions, allergenic glycan would be contaminated to a certain degree. Our goal is to make user-friendly tools for such glyco-qualification.
Mostly, LC and Mass spectrometry. But, for simple testing, lectin-based technologies are applicable. Researchers have available many types of lectins with different specificities and each lectin binds to some specific glycans. So, we can estimate glycan structures using multiuse of lectin-by-lectin blotting, lectin ELISA, and lectin microarray.
Glycosylation occurs in functional proteins in our body. Glycan structure is altered along with diseases. Nowadays, we have used several disease-specific glycosylations as diagnostic biomarkers, such as CA 19-9 and AFP-L3. Notably, new biomarker candidates have been discovered using lectin-based technologies. For their validation, we need glyco-qualification system.
Glyco-qualification is hard work. We need to analyze hundreds or thousands of numbers in a short time. However, there is no system to meet the needs. Our analytical method is the only one with a full-automatic measurement process. It drastically reduces manpower and enables us to conduct effective validation.
Our work aims to further improve our rapid instrument, especially for quantitative measurement. After this, we expect to realize a unique diagnostic tool with "glycobiomarker panel" measured by our multilectin system. Hence, we are focusing on the discovery of disease-specific glycobiomarkers.
